Neoleukin Therapeutics Inc (NLTX) WACC Analysis

As of June 4, 2025, Neoleukin Therapeutics Inc (NLTX) carries a Weighted Average Cost of Capital (WACC) of 11.5%. WACC reflects the blended rate Neoleukin Therapeutics Inc must pay to both equity and debt holders.

Within that, the cost of equity is 9.9%, the cost of debt is 5.0%, and the effective tax rate is 26.2%.

Breakdown of WACC Components

• Long-term bond rate: 4.2% – 4.7%
• Equity market risk premium: 5.0% – 6.0%
• Adjusted beta: 1.14 – 1.35
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.01

What It Means for Investors

With a selected WACC of 11.5%, Neoleukin Therapeutics Inc must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects a relatively high financing requirement.